GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » UroGen Pharma Ltd (LTS:0XOD) » Definitions » Margin of Safety % (DCF FCF Based)

UroGen Pharma (LTS:0XOD) Margin of Safety % (DCF FCF Based) : N/A (As of Apr. 25, 2025)


View and export this data going back to 2018. Start your Free Trial

What is UroGen Pharma Margin of Safety % (DCF FCF Based)?

Margin of Safety % (DCF FCF Based) = (Intrinsic Value: DCF (FCF Based) - Current Price) / Intrinsic Value: DCF (FCF Based).

Note: Discounted FCF model is only suitable for predictable companies (Business Predictability Rank higher than 1-Star). If the company's Predictability Rank is 1-Star or Not Rated, result may not be accurate due to the low predictability of business and the data will not be stored into our database.

UroGen Pharma's Predictability Rank is Not Rated. Thus, the DCF related results in the screener and portfolio will appear as zero and Margin of Safety % (DCF FCF Based) is not calculated.

Competitive Comparison of UroGen Pharma's Margin of Safety % (DCF FCF Based)

For the Biotechnology subindustry, UroGen Pharma's Margin of Safety % (DCF FCF Based), along with its competitors' market caps and Margin of Safety % (DCF FCF Based) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

UroGen Pharma's Margin of Safety % (DCF FCF Based) Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, UroGen Pharma's Margin of Safety % (DCF FCF Based) distribution charts can be found below:

* The bar in red indicates where UroGen Pharma's Margin of Safety % (DCF FCF Based) falls into.


;
;

UroGen Pharma Margin of Safety % (DCF FCF Based) Related Terms

Thank you for viewing the detailed overview of UroGen Pharma's Margin of Safety % (DCF FCF Based) provided by GuruFocus.com. Please click on the following links to see related term pages.

UroGen Pharma Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » UroGen Pharma Ltd (LTS:0XOD) » Definitions » Margin of Safety % (DCF FCF Based)
Comparable Companies
TYRA ARVN SION SAGE CAPR NAGE SVRA MAZE OMER IMTX VRTX ASX:CSL REGN XKRX:207940 XBRU:ARGX ALNY XBRU:UCB ONC XKRX:068270 BNTX
Traded in Other Exchanges
URGN:USA UR8:Germany
Address
400 Alexander Park Drive, 4th Floor, Princeton, NJ, USA, 08540
Website
https://www.urogen.com
UroGen Pharma Ltd is a clinical-stage biotechnology firm specializing in solutions for urothelial and specialty cancers. The company has developed RTGel reverse-thermal hydrogel, a proprietary technology enhancing the therapeutic profiles of existing drugs by enabling sustained release. Their flagship product, Jelmyto (mitomycin) for pyelocalyceal solution, along with investigational candidate UGN-102 (mitomycin) for intravesical solution, targets non-surgical tumor ablation in forms of non-muscle invasive urothelial cancer. Additionally, their immuno-uro-oncology pipeline includes UGN-301 (zalifrelimab), an anti-CTLA-4 antibody, intended for both monotherapy and combination therapy. Revenue is generated from product sales.

UroGen Pharma Headlines

No Headlines